Amgen Inc. (NASDAQ:AMGN) Stock Position Increased by Huntington National Bank

Huntington National Bank boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,132 shares of the medical research company’s stock after buying an additional 1,095 shares during the quarter. Huntington National Bank’s holdings in Amgen were worth $13,066,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in Amgen in the third quarter worth approximately $150,000. IHT Wealth Management LLC boosted its stake in shares of Amgen by 10.5% during the 3rd quarter. IHT Wealth Management LLC now owns 12,765 shares of the medical research company’s stock worth $4,111,000 after acquiring an additional 1,210 shares in the last quarter. Motley Fool Asset Management LLC grew its holdings in shares of Amgen by 3.8% in the 3rd quarter. Motley Fool Asset Management LLC now owns 21,627 shares of the medical research company’s stock worth $6,928,000 after acquiring an additional 784 shares during the last quarter. Morse Asset Management Inc acquired a new stake in shares of Amgen during the third quarter worth $806,000. Finally, Reynders McVeigh Capital Management LLC boosted its position in shares of Amgen by 4.4% in the 3rd quarter. Reynders McVeigh Capital Management LLC now owns 9,455 shares of the medical research company’s stock valued at $3,046,000 after purchasing an additional 402 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Down 0.4 %

Shares of NASDAQ:AMGN opened at $305.70 on Thursday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market cap of $164.22 billion, a P/E ratio of 40.49, a P/E/G ratio of 2.63 and a beta of 0.53. The stock’s 50-day moving average is $303.16 and its 200-day moving average is $297.69. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.11%. Amgen’s dividend payout ratio is currently 126.09%.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Bank of America boosted their price objective on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 29th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $314.04.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now directly owns 62,147 shares in the company, valued at $18,222,743.34. This represents a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.